Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study.

Fabrizio MartoraClaudio MarascaSara CacciapuotiFederica FarielloLuca PotestioTeresa BattistaMassimiliano ScalvenziMatteo Megna

Published in: Clinical, cosmetic and investigational dermatology (2024)

The results of our study highlight that treatment with secukinumab in patients with severe HS who failed adalimumab may be a safe and effective therapeutic weapon.

Keyphrases

hidradenitis suppurativa
ankylosing spondylitis
juvenile idiopathic arthritis
clinical trial
systemic lupus erythematosus
disease activity
combination therapy
placebo controlled